wherein a when X is NH or N CH 3, R 3 is selected from chlorine and cyano; and b when X is O, R 3 is CN; iv a group CR 6 R 7 R 8 wherein R 6 and R 7 are each selected from hydrogen and methyl, and R 8 is selected from hydrogen, methyl, C 1 4 alkylsulphonylmethyl, hydroxymethyl and cyano; v a pyridazin 4 yl group optionally substituted by one or two substituents selected from methyl, ethyl, methoxy and ethoxy; vi a substituted imidazothiazole group wherein the substituents are selected from methyl, ethyl, amino, fluorine, chlorine, amino and methylamino; and vii an optionally substituted 1, 3 dihydro isoindol 2 yl or optionally substituted 2, 3 dihydro indol 1 yl group wherein the optional substituents in each case are selected from halogen, cyano, amino, C 1 4 mono and dialkylamino, CONH 2 or CONH C 1 4 alkyl C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino; viii 3 pyridyl optionally substituted by one or two substituents selected from hydroxy, halogen, cyano, amino, C 4 4 mono and dialkylamino, CONH 2 or CONH C 1 4 alkyl, C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino, but excluding the compounds 2 oxo 1, 2 dihydro pyridine 3 carboxylic acid 3 5 morpholin 4 ylmethyl 1H benzoimidazol 2 yl 1H pyrazol 4 yl amide and 2, 6 dimethoxy N 3 5 morpholin 4 ylmethyl 1H benzoimidazol 2 yl 1H pyrazol 4 yl nicotinamide; ix thiomorpholine or an S oxide or S, S dioxide thereof optionally substituted by one or two substitutents selected from halogen, cyano, amino, C 1 4 mono and dialkylamino, CONH 2 or CONH C 1 4 alkyl C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino; and when E A is NR 2, R 1 is additionally selected from x 2 fluorophenyl, 3 fluorophenyl, 4 fluorophenyl, 2, 4 difluorophenyl, 3, 4 difluorophenyl, 2, 5 difluorophenyl, 3, 5 difluorophenyl, 2, 4, 6 trifluorophenyl, 2 methoxyphenyl, 5 chloro 2 methoxyphenyl, cyclohexyl, unsubstituted 4 tetrahydropyranyl and tert butyl; xi a group NR 10 R 11 where R 10 and R 11 are each C 1 4 alkyl or R 10 and R 11 are linked so that NR 10 R 11 forms a saturated heterocyclic group of 4 to 6 ring members optionally containing a second heteroatom ring member selected from O, N, S and SO 2, the heterocyclic group being optionally substituted by C 1 4 alkyl, amino or hydroxy; xii pyridone optionally substituted by one or two substituents selected from hydroxy, halogen, cyano, amino, C 1 4 mono and dialkylamino, CONH 2, CONH C 1 4 alkyl, C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino; when E A is C CH 3 2 NR 2 or CH 2 NR 2, R 1 is additionally selected from xiii unsubstituted 2 furyl and 2, 6 difluorophenyl; and when E A is C CH 3 2 NR 2, R 1 is additionally selected from xiv unsubstituted phenyl; and when E is CH 2, R 1 is additionally selected from xv unsubstituted tetrahydropyran 4 yl; and B when M is a group D2 A is selected from a bond and a group NR 2 where R 2 is hydrogen or methyl; E is selected from a bond, CH 2, CH CN and C CH 3 2; R 1 is selected from xvi a 2 substituted 3 furyl group of the formula cheapest priligy uk
wherein a when X is NH or N CH 3, R 3 is selected from chlorine and cyano; and b when X is O, R 3 is CN; iv a group CR 6 R 7 R 8 wherein R 6 and R 7 are each selected from hydrogen and methyl, and R 8 is selected from hydrogen, methyl, C 1 4 alkylsulphonylmethyl, hydroxymethyl and cyano; v a pyridazin 4 yl group optionally substituted by one or two substituents selected from methyl, ethyl, methoxy and ethoxy; vi a substituted imidazothiazole group wherein the substituents are selected from methyl, ethyl, amino, fluorine, chlorine, amino and methylamino; and vii an optionally substituted 1, 3 dihydro isoindol 2 yl or optionally substituted 2, 3 dihydro indol 1 yl group wherein the optional substituents in each case are selected from halogen, cyano, amino, C 1 4 mono and dialkylamino, CONH 2 or CONH C 1 4 alkyl C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino; viii 3 pyridyl optionally substituted by one or two substituents selected from hydroxy, halogen, cyano, amino, C 4 4 mono and dialkylamino, CONH 2 or CONH C 1 4 alkyl, C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino, but excluding the compounds 2 oxo 1, 2 dihydro pyridine 3 carboxylic acid 3 5 morpholin 4 ylmethyl 1H benzoimidazol 2 yl 1H pyrazol 4 yl amide and 2, 6 dimethoxy N 3 5 morpholin 4 ylmethyl 1H benzoimidazol 2 yl 1H pyrazol 4 yl nicotinamide; ix thiomorpholine or an S oxide or S, S dioxide thereof optionally substituted by one or two substitutents selected from halogen, cyano, amino, C 1 4 mono and dialkylamino, CONH 2 or CONH C 1 4 alkyl C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino; and when E A is NR 2, R 1 is additionally selected from x 2 fluorophenyl, 3 fluorophenyl, 4 fluorophenyl, 2, 4 difluorophenyl, 3, 4 difluorophenyl, 2, 5 difluorophenyl, 3, 5 difluorophenyl, 2, 4, 6 trifluorophenyl, 2 methoxyphenyl, 5 chloro 2 methoxyphenyl, cyclohexyl, unsubstituted 4 tetrahydropyranyl and tert butyl; xi a group NR 10 R 11 where R 10 and R 11 are each C 1 4 alkyl or R 10 and R 11 are linked so that NR 10 R 11 forms a saturated heterocyclic group of 4 to 6 ring members optionally containing a second heteroatom ring member selected from O, N, S and SO 2, the heterocyclic group being optionally substituted by C 1 4 alkyl, amino or hydroxy; xii pyridone optionally substituted by one or two substituents selected from hydroxy, halogen, cyano, amino, C 1 4 mono and dialkylamino, CONH 2, CONH C 1 4 alkyl, C 1 4 alkyl and C 1 4 alkoxy wherein the C 1 4 alkyl and C 1 4 alkoxy groups are optionally substituted by hydroxy, methoxy, or amino; when E A is C CH 3 2 NR 2 or CH 2 NR 2, R 1 is additionally selected from xiii unsubstituted 2 furyl and 2, 6 difluorophenyl; and when E A is C CH 3 2 NR 2, R 1 is additionally selected from xiv unsubstituted phenyl; and when E is CH 2, R 1 is additionally selected from xv unsubstituted tetrahydropyran 4 yl; and B when M is a group D2 A is selected from a bond and a group NR 2 where R 2 is hydrogen or methyl; E is selected from a bond, CH 2, CH CN and C CH 3 2; R 1 is selected from xvi a 2 substituted 3 furyl group of the formula cheapest priligy uk